MA32455B1 - Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1 - Google Patents

Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1

Info

Publication number
MA32455B1
MA32455B1 MA33493A MA33493A MA32455B1 MA 32455 B1 MA32455 B1 MA 32455B1 MA 33493 A MA33493 A MA 33493A MA 33493 A MA33493 A MA 33493A MA 32455 B1 MA32455 B1 MA 32455B1
Authority
MA
Morocco
Prior art keywords
edg
formula
compounds represented
oxazolopyrimidines
receptor agonists
Prior art date
Application number
MA33493A
Other languages
Arabic (ar)
English (en)
Inventor
Dieter Kadereit
Matthias Schaefer
Werngard Czechtizky
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32455B1 publication Critical patent/MA32455B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention porte sur des composés oxazolopyrimidines représentés par la formule i dans laquelle a, r1, r2 et r3 sont définis comme indiqué dans les revendications. Les composés représentés par la formule i modulent l'activité du récepteur edg-1 et en particulier sont des agonistes de ce récepteur et sont utiles pour le traitement de maladies telles que l'athérosclérose, l'insuffisance cardiaque ou une maladie oblitérante artérielle périphérique, par exemple. L'invention porte en outre sur des procédés pour la fabrication de composés représentés par la formule i, sur leur utilisation, en particulier comme ingrédients actifs dans des produits pharmaceutiques, et sur des compositions pharmaceutiques les comprenant.
MA33493A 2008-07-15 2011-01-05 Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1 MA32455B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290694 2008-07-15
PCT/EP2009/004770 WO2010006704A1 (fr) 2008-07-15 2009-07-02 Oxazolopyrimidines comme agonistes du récepteur edg-1

Publications (1)

Publication Number Publication Date
MA32455B1 true MA32455B1 (fr) 2011-07-03

Family

ID=39967817

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33493A MA32455B1 (fr) 2008-07-15 2011-01-05 Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1

Country Status (20)

Country Link
US (1) US8735387B2 (fr)
EP (2) EP2583720A1 (fr)
JP (1) JP5449346B2 (fr)
KR (1) KR20110042286A (fr)
CN (1) CN102159582B (fr)
AR (1) AR072496A1 (fr)
AU (1) AU2009270511B2 (fr)
BR (1) BRPI0915781A2 (fr)
CA (1) CA2730843A1 (fr)
CL (1) CL2011000071A1 (fr)
CO (1) CO6331436A2 (fr)
IL (1) IL210639A0 (fr)
MA (1) MA32455B1 (fr)
MX (1) MX2011000211A (fr)
NZ (1) NZ590377A (fr)
RU (1) RU2503680C2 (fr)
TW (1) TW201016707A (fr)
UY (1) UY31981A (fr)
WO (1) WO2010006704A1 (fr)
ZA (1) ZA201008786B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
UY33177A (es) 2010-01-13 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido
SG182474A1 (en) * 2010-01-14 2012-08-30 Sanofi Sa Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
EP2523963B1 (fr) * 2010-01-14 2014-08-27 Sanofi Dérivés de l'oxazolopyrimidine à substitution 2,5 en tant qu'agonistes du récepteur edg-1
RS53254B (en) * 2010-01-14 2014-08-29 Sanofi CARBOXYLIC ACID DERIVATIVES WITH 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING
WO2011111831A1 (fr) 2010-03-12 2011-09-15 日本曹達株式会社 Composé contenant un noyau pyridine et procédé pour la production d'un dérivé halogéné de picoline et d'un dérivé de tétrazolyloxime
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
US8907093B2 (en) 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
CN104540835B (zh) * 2012-04-26 2017-08-08 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
HUE060743T2 (hu) * 2012-04-26 2023-04-28 Bristol Myers Squibb Co Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére
US10577308B2 (en) 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3679682A (en) * 1970-04-23 1972-07-25 Fmc Corp CERTAIN 5H-ISOXAZOLO{8 5,4-d{9 PYRIMIDIN-4-ONES
ES2259707T3 (es) * 2001-05-14 2006-10-16 Novartis Ag Oxazolo y furopirimidinas y su uso en medicamentos contra tumores.
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
EP1622913A1 (fr) 2003-04-25 2006-02-08 University College Cardiff Consultants, Ltd. Composes heterocycliques destines a etre utilises dans le traitement d'infections virales
WO2004096757A1 (fr) * 2003-04-30 2004-11-11 Novartis Ag Derives d'amino-propanol comme modulateurs de recepteur de sphingosine-1-phosphate
CL2004001120A1 (es) * 2003-05-19 2005-04-15 Irm Llc Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
EP1666468A4 (fr) 2003-09-09 2007-03-21 Ono Pharmaceutical Co Antagonistes crf et composes heterobicycliques
EP1697333A4 (fr) 2003-12-17 2009-07-08 Merck & Co Inc Carboxylates propanoiques 3,4-disusbstitues utilises en tant qu'agonistes du recepteur s1p (edg)
US20050165029A1 (en) 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005123677A1 (fr) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd Utilisation de derives de 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa[a]pentalene a substitution 4-carbonyle comme agonistes du recepteur couple aux proteines g s1p1/edg1 et agents immunosuppresseurs
WO2006010379A1 (fr) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Nouveaux derives du thiophene utilises comme agents immunosupresseurs
WO2006047195A2 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
US7855193B2 (en) 2005-11-23 2010-12-21 Epix Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
EP1900729A1 (fr) * 2006-09-15 2008-03-19 Novartis AG Benzoxazoles et oxazolopyridines et leur utilisation comme inhibiteurs de Janus kinases

Also Published As

Publication number Publication date
KR20110042286A (ko) 2011-04-26
BRPI0915781A2 (pt) 2015-11-10
EP2318415A1 (fr) 2011-05-11
JP5449346B2 (ja) 2014-03-19
CO6331436A2 (es) 2011-10-20
CN102159582A (zh) 2011-08-17
AU2009270511B2 (en) 2013-07-18
EP2318415B1 (fr) 2013-02-20
WO2010006704A1 (fr) 2010-01-21
RU2503680C2 (ru) 2014-01-10
CN102159582B (zh) 2014-05-07
US8735387B2 (en) 2014-05-27
CL2011000071A1 (es) 2011-05-06
AR072496A1 (es) 2010-09-01
JP2011527994A (ja) 2011-11-10
AU2009270511A1 (en) 2010-01-21
NZ590377A (en) 2011-11-25
MX2011000211A (es) 2011-03-03
CA2730843A1 (fr) 2010-01-21
TW201016707A (en) 2010-05-01
EP2583720A1 (fr) 2013-04-24
US20110190490A1 (en) 2011-08-04
RU2011105388A (ru) 2012-08-20
IL210639A0 (en) 2011-03-31
UY31981A (es) 2010-02-26
ZA201008786B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
MA32455B1 (fr) Oxazolopyrimidines en tant qu'agonistes des récepteurs edg-1
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MY155836A (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
TN2011000201A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase - iv inhibitors for the treatment or prevention of diabetes
PT2150530E (pt) Derivados de sulfonamida substituídos
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
MX2010009654A (es) Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
MX2013007558A (es) 1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
TW200602330A (en) Compounds and compositions as PPAR modulators
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX367131B (es) Sales de xantilio 3,6-disustituidas.
EP2257161A4 (fr) Inhibiteurs de l'ahcy hydrolase destinés au traitement de l'hyper-homocystéinémie
EA201001586A1 (ru) Соединения и композиции в качестве ингибиторов itpkb
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
NO20090067L (no) Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer